The addition of entinostat to exemestane improved PFS for patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to randomized phase 3 study results presented at San Antonio Breast Cancer Symposium.“The oral histone deacetylase inhibitor entinostat [SNDX-275, Syndax] has been investigated globally in more than 50 clinical trials as monotherapy and in